E García-Giralt

1.2k total citations
63 papers, 943 citations indexed

About

E García-Giralt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, E García-Giralt has authored 63 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 16 papers in Immunology. Recurrent topics in E García-Giralt's work include Cancer Treatment and Pharmacology (15 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). E García-Giralt is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). E García-Giralt collaborates with scholars based in France, United States and Netherlands. E García-Giralt's co-authors include P Pouillart, T Palangié, M Jouve, Thierry Dorval, Pierre Kerbrat, M. Namer, P. Fumoleau, F.M. Delgado, R Keiling and T. Delozier and has published in prestigious journals such as Nature, Science and Journal of Clinical Oncology.

In The Last Decade

E García-Giralt

62 papers receiving 873 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E García-Giralt France 13 577 332 195 147 129 63 943
M Giai Italy 18 460 0.8× 268 0.8× 474 2.4× 165 1.1× 106 0.8× 33 1.2k
J.H. Holzner Austria 16 364 0.6× 178 0.5× 292 1.5× 100 0.7× 102 0.8× 49 858
Massimo Fanelli Italy 17 423 0.7× 310 0.9× 555 2.8× 64 0.4× 132 1.0× 26 1.0k
Mark Edinger United States 19 393 0.7× 145 0.4× 270 1.4× 481 3.3× 140 1.1× 45 1.0k
Alessandra Bersiga Italy 16 641 1.1× 658 2.0× 458 2.3× 149 1.0× 146 1.1× 31 1.2k
W J Urba United States 18 722 1.3× 208 0.6× 252 1.3× 510 3.5× 202 1.6× 33 1.3k
S Romain France 17 611 1.1× 316 1.0× 348 1.8× 50 0.3× 185 1.4× 43 965
Frank Mross Switzerland 3 515 0.9× 362 1.1× 521 2.7× 50 0.3× 153 1.2× 7 1.0k
C. Pallud France 18 700 1.2× 479 1.4× 387 2.0× 183 1.2× 170 1.3× 32 1.2k
Thorunn Helgason United States 15 427 0.7× 342 1.0× 467 2.4× 73 0.5× 166 1.3× 31 1.1k

Countries citing papers authored by E García-Giralt

Since Specialization
Citations

This map shows the geographic impact of E García-Giralt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E García-Giralt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E García-Giralt more than expected).

Fields of papers citing papers by E García-Giralt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E García-Giralt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E García-Giralt. The network helps show where E García-Giralt may publish in the future.

Co-authorship network of co-authors of E García-Giralt

This figure shows the co-authorship network connecting the top 25 collaborators of E García-Giralt. A scholar is included among the top collaborators of E García-Giralt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E García-Giralt. E García-Giralt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
García-Giralt, E, et al.. (2007). 804 POSTER Conditioning of vaccine sentinel lymph node as adjuvant of autologous hemoderivative breast cancer vaccine. European Journal of Cancer Supplements. 5(4). 118–118. 1 indexed citations
2.
Vázquez, J., et al.. (2006). Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative. Breast Cancer Research and Treatment. 100(2). 149–160. 11 indexed citations
3.
García-Giralt, E, et al.. (1997). [The role of metastron in the treatment of prostate cancer].. PubMed. 148(1-2). 1–5.
4.
García-Giralt, E, Philippe Beuzeboc, Véronique Dièras, et al.. (1996). Phase II Trial of Decapeptyl (D-TRP-6), a Potent Luteinizing Hormone-Releasing Hormone Analogue in Untreated Advanced Breast Cancer. American Journal of Clinical Oncology. 19(5). 455–458. 6 indexed citations
5.
Raymond, Éric, T Palangié, Michel Jouve, et al.. (1996). Protracted Continuous Infusion of 5-Fluorouracil in Combination with Doxorubicin, Vincristine, and Oral Cyclophospharnide in Advanced Breast Cancer. Cancer Investigation. 14(2). 91–97. 5 indexed citations
6.
Pierga, J-Y, Véronique Dièras, Thierry Dorval, et al.. (1996). Treatment of Advanced or Recurrent Endometrial Carcinoma with Combination of Etoposide, Cisplatin, and 5-Fluorouracil: A Phase II Study. Gynecologic Oncology. 60(1). 59–63. 14 indexed citations
7.
Jouve, M, B Asselain, Thierry Dorval, et al.. (1995). Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer.. PubMed. 5(4). 197–200. 3 indexed citations
8.
Fumoleau, P., F.M. Delgado, T. Delozier, et al.. (1993). Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.. Journal of Clinical Oncology. 11(7). 1245–1252. 281 indexed citations
9.
Beuzeboc, Philippe, Thierry Dorval, E García-Giralt, et al.. (1993). [Malignant epidermoid degeneration of dermoid cysts of the ovary. Apropos of 2 cases].. PubMed. 47(7). 641–4. 5 indexed citations
10.
Beuzeboc, Philippe, Thierry Dorval, E García-Giralt, et al.. (1988). [Encephalopathy caused by an ifosfamide-mesna combination].. PubMed. 17(12). 591–2. 1 indexed citations
11.
Dorval, Thierry, T Palangié, M Jouve, et al.. (1987). Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b. Investigational New Drugs. 5(S4). S61–S63. 10 indexed citations
12.
Pouillart, P, M Jouvet, T Palangié, et al.. (1985). [Hepatic metastases of breast cancer. Analysis of the parameters which influence the response to chemotherapy].. PubMed. 21(2). 87–90. 6 indexed citations
13.
Pouillart, P, et al.. (1982). [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].. PubMed. 69(5). 461–7. 2 indexed citations
14.
Lenfant, Maryse, et al.. (1980). The purification of an immunosuppressive factor extracted from bovine spleen—III. Molecular Immunology. 17(1). 119–126. 10 indexed citations
15.
García-Giralt, E, et al.. (1978). Purification of Immunosuppressive Factors Extracted From Bovine Spleen (Lymphoid Chalone). Cell Proliferation. 11(5). 465–476. 6 indexed citations
16.
Mathé, G, N Kiger, I. Florentin, et al.. (1973). Progress in the prevention of GVH: bone marrow grafts after ALG conditioning, with lymphocyte split chimerism, use of a lymphocyte "chalone T", and soluble histocompatibility antigens.. PubMed. 5(1). 933–9. 12 indexed citations
17.
Kiger, N, I. Florentin, E García-Giralt, & G Mathé. (1973). Inhibition of graft-versus-host-reaction (GVHR) by in vitro incubation of donor lymphocytes with thymic or splenic chalone (s).. PubMed. 1(1). 22–8. 6 indexed citations
18.
García-Giralt, E. (1972). Inhibitor of DNA in Lymphocytic Cells. Science. 176(4032). 316–316. 3 indexed citations
19.
García-Giralt, E, et al.. (1971). Extraction of an inhibitor of DNA synthesis from human peripheral blood lymphocytes and bovine spleen.. PubMed. 15(7). 789–92. 33 indexed citations
20.
García-Giralt, E, et al.. (1970). Growth Inhibitory Activity in the Supernatants of Nondividing WI-38 Cells. JNCI Journal of the National Cancer Institute. 45(4). 649–55. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Giai Breakdown of academic impact, for papers by J.H. Holzner Breakdown of academic impact, for papers by Massimo Fanelli Breakdown of academic impact, for papers by Mark Edinger Breakdown of academic impact, for papers by Alessandra Bersiga Breakdown of academic impact, for papers by W J Urba Breakdown of academic impact, for papers by S Romain Breakdown of academic impact, for papers by Frank Mross Breakdown of academic impact, for papers by C. Pallud Breakdown of academic impact, for papers by Thorunn Helgason
Rankless by CCL
2026